Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Opeyemi Udoka
Institutions:
United States Food and Drug Administration,
Center for Drug Evaluation and Research
Observed institutions:
United States Food and Drug Administration,
Center for Drug Evaluation and Research
ORCID:
0009-0009-4923-3001
Observed ORCID:
0009-0009-4923-3001
OpenAlex ID:
A5099127770
FDA Approval Summary: Tovorafenib for Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma
2025
·
Sonia Singh
, Diana Bradford
, et al.
·
Clinical Cancer Research
·
36
FDA Approval Summary: Repotrectinib for Locally Advanced or Metastatic ROS1-Positive Non–Small Cell Lung Cancer
2024
·
Michael I. Barbato
, Diana Bradford
, et al.
·
Clinical Cancer Research
·
19
PDF
Supplementary Table S1 from FDA Approval Summary: Tovorafenib for Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma
2025
·
Sonia Singh
, Diana Bradford
, et al.
·
1
Data from FDA Approval Summary: Tovorafenib for Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma
2025
·
Sonia Singh
, Diana Bradford
, et al.
Show more works
View as search
Works count:
4
Citation count:
56
H-index:
2
I10-index:
2
Year
Topic
Type